Search

Your search keyword '"Ellis, I.O."' showing total 633 results
Start Over Author "Ellis, I.O."
633 results on '"Ellis, I.O."'

20. Three-dimensional reconstruction of sentinel lymph nodes with metastatic breast cancer indicates three distinct patterns of tumour growth

Author

Paish, E.C., Green, A.R., Rakha, E.A., Macmillan, R.D., Maddison, J.R., and Ellis, I.O.

Subjects
Breast cancer -- Genetic aspects, Breast cancer -- Development and progression, Breast cancer -- Diagnosis, Breast cancer -- Research, Axillary dissection -- Usage, Metastasis -- Research, Three-dimensional display systems -- Usage, Three-dimensional display systems -- Research, Cancer -- Diagnosis, Cancer -- Research, 3D technology, Health
Published
2009

21. MicroRNA involvement in the pathogenesis and management of breast cancer

Author

Khoshnaw, S.M., Green, A.R., Powe, D.G., and Ellis, I.O.

Subjects
Breast cancer -- Diagnosis, Breast cancer -- Care and treatment, Breast cancer -- Genetic aspects, RNA -- Research, RNA -- Physiological aspects, Gene expression -- Research, Gene expression -- Physiological aspects, Health
Published
2009

22. HER2 testing in the UK: further update to recommendations

Author

Walker, R.A., Bartlett, J.M.S., Dowsett, M., Ellis, I.O., Hanby, A.M., Jasani, B., Miller, K., and Pinder, S.E.

Subjects
Breast cancer -- Diagnosis, Genetic screening -- Forecasts and trends, Practice guidelines (Medicine) -- Evaluation, Market trend/market analysis, Health
Published
2008

27. Guidelines on the standards for the training of specialised health professionals dealing with breast cancer

Author

Cataliotti, L., De Wolf, C., Holland, R., Marotti, L., Perry, N., Redmond, K., Rosselli Del Turco, M., Rijken, H., Kearney, N., Ellis, I.O., Di Leo, A., Orecchia, R., Noel, A., Andersson, M., Audretsch, W., Bjurstam, N., Blamey, R.W., Blichert-Toft, M., Bosmans, H., Burch, A., Bussolati, G., Christiaens, M.R., Colleoni, M., Cserni, G., Cufer, T., Cush, S., Damilakis, J., Drijkoningen, M., Ellis, P., Foubert, J., Gambaccini, M., Gentile, E., Guedea, F., Hendriks, J., Jakesz, R., Jassem, J., Jereczek-Fossa, B.A., Laird, O., Lartigau, E., Mattheiem, W., O’Higgins, N., Pennery, E., Rainsbury, D., Rutgers, E., Smola, M., Van Limbergen, E., von Smitten, K., Wells, C., and Wilson, R.

Published
2007
Full Text
View/download PDF

28. Impact of a national external quality assessment scheme for breast pathology in the UK

Author

Ellis, I.O., Coleman, D., Wells, C., Kodikara, S., Paish, E.M., Moss, S., Al-sam, S., Anderson, N., Bobrow, L., Buley, I., Connolly, C.E., Dallimore, N.S., Hales, S., Hanby, A., Humphreys, S., Knox, F., Lowe, J., Macartney, J., Nash, R., Parham, D., Patnick, J., Pinder, S.E., Quinn, C.M., Robertson, A.J., Shrimankar, J., Walker, R.A., and Winder, R.

Subjects
United Kingdom. National Health Service -- Standards, Pathologists -- Evaluation, Breast cancer -- Diagnosis, Breast cancer -- Development and progression, Cancer -- Diagnosis, Cancer -- Standards, Health
Published
2006

29. The NHS breast screening programme (pathology) EQA: experience in recent years relating to issues involved in individual performance appraisal

Author

Parham, D.M., Coleman, D., Kodikara, S., Moss, S., Ellis, I.O., Al-sam, S., Anderson, N., Bobrow, L., Buley, I., Connolly, C.E., Dallimore, N.S., Hales, S., Hanby, A., Humphreys, S., Knox, F., Lowe, J., Macartney, J., Nash, R., Patrick, J., Pinder, S.E., Quinn, C.M., Robertson, A.J., Shrimankar, J., Walker, R.A., Wells, C., Winder, R., and Patel, N.

Subjects
United Kingdom. National Health Service -- Standards, Breast examination -- Management, Breast diseases -- Development and progression, Pathologists -- Management, Performance standards -- Research, Company business management, Health
Published
2006

34. Updated recommendations for HER2 testing in the UK

Author

Ellis, I.O., Bartlett, J., Dowsett, M., Humphreys, S., Jasani, B., Miller, K., Pinder, S.E., Rhodes, A., and Walker, R.

Abstract

This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of [...]

Published
2004

38. Expression of Lamin A/C in early-stage breast cancer and its prognostic value

Author

Alhudiri, I.M., Ellis, I.O., Elzagheid, A., Rakha, E.A., Green, A.R., Chapman, C.J., and Nolan, C.C.

Subjects
Lamin A/C, Breast cancer, Nottingham Breast Cancer Research Centre, Prognosis, Immunohistochemistry, Tissue microarray
Abstract

Purpose: Lamins A/C, a major component of the nuclear lamina, plays key roles in maintaining nuclear integrity, regulation of gene expression, cell proliferation and apoptosis. Reduced lamin A/C expression in cancer has been reported to be a sign of poor prognosis. However, its clinical significance in breast cancer remains to be defined. This study aimed to evaluate expression and prognostic significance of lamin A/C in early-stage breast cancer.Methods: Using immunohistochemical staining of tissue microarrays, expression of lamin A/C was evaluated in a large well-characterised series of early-stage operable breast cancer (n=938) obtained from Nottingham Primary Breast Carcinoma Series. Association of lamin A/C expression with clinicopathological parameters and outcome was evaluated.Results: Positive expression rate of lamin A/C in breast cancer was 42.2% (n=398). Reduced/loss of expression of lamin A/C was significantly associated with high histological grade (p [less than] 0.001), larger tumour size (p=0.004), poor Nottingham Prognostic Index (NPI) score (p [less than] 0.001), lymphovascular invasion (p=0.014) and development of distant metastasis (p=0.027). Survival analysis showed that reduced/loss of expression of lamin A/C was significantly associated with shorter breast cancer specific survival (p=0.008).Conclusion: This study suggests lamin A/C plays a role in breast cancer and loss of its expression is associated with variables of poor prognosis and shorter outcome.

Published
2019

43. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines

Author

Cserni, G., Amendoeira, I., Apostolikas, N., Bellocq, J.P., Bianchi, S., Bussolati, G., Boecker, W., Borisch, B., Connolly, C.E., Decker, T., Dervan, P., Drijkoningen, M., Ellis, I.O., Elston, C.W., Eusebi, V., Faverly, D., Heikkila, P., Holland, R., Kerner, H., Kulka, J., Jacquemier, J., Lacerda, M., Martinez-Penuela, J., De Miguel, C., Peterse, J.L., Rank, F., Regitnig, P., Reiner, A., Sapino, A., Sigal-Zafrani, B., Tanous, A.M., Thorstenson, S., Zozaya, E., and Wells, C.A.

Published
2003
Full Text
View/download PDF

46. Short- and long-term effects of a training session on pathologists' performance: the INQAT experience for histological grading in breast cancer

Author

Paradiso, A., Ellis, I.O., Zito, F.A., Marubini, E., Pizzamiglio, S., and Verderio, P.

Subjects
Breast cancer -- Diagnosis, Breast cancer -- Research, Pathologists -- Training, Pathologists -- Research, Clinical competence -- Research, Medical personnel -- Training, Medical personnel -- Influence, Medical personnel -- Research, Health
Published
2009

47. Combining Clustering and Classification Ensembles: A Novel Pipeline to Identify Breast Cancer Profiles

Author

Agrawal, U., Soria, D., Wagner, C., Garibaldi, J.M., Ellis, I.O., Bartlett, J.M.S., Cameron, D., Rakha, E.A., and Green, A.R.

Subjects
Ensemble Clustering, Ensemble Classification, Class level fusion, Refining cluster results, Breast Cancer, Pipeline
Abstract

Breast Cancer is one of the most common causes of cancer death in women, representing a very complex disease with varied molecular alterations. To assist breast cancer prognosis, the classification of patients into biological groups is of great significance for treatment strategies. Recent studies have used an ensemble of multiple clustering algorithms to elucidate the most characteristic biological groups of breast cancer. However, the combination of various clustering methods resulted in a number of patients remaining unclustered. Therefore, a framework still needs to be developed which can assign as many unclustered (i.e. biologically diverse) patients to one of the identified groups in order to improve classification. Therefore, in this paper we develop a novel classification framework which introduces a new ensemble classification stage after the ensemble clustering stage to target the unclustered patients. Thus, a step-by-step pipeline is introduced which couples ensemble clustering with ensemble classification for the identification of core groups, data distribution in them and improvement in final classification results by targeting the unclustered data. The proposed pipeline is employed on a novel real world breast cancer dataset and subsequently its robustness and stability are examined by testing it on standard datasets. The results show that by using the presented framework, an improved classification is obtained. Finally, the results have been verified using statistical tests, visualisation techniques, cluster quality assessment and interpretation from clinical experts.

Published
2019
Full Text
View/download PDF

48. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer

Author

El Ansari, R., Craze, M.L., Alfarsi, L., Soria, D., Diez-Rodriguez, M., Nolan, C.C., Ellis, I.O., Rakha, E.A., and Green, A.R.

Subjects
SLC1A5, SLC7A5, SLC3A2, clusters, breast cancer, prognosis
Abstract

Purpose: Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity, and patient outcome. Glutamine availability for growth and progression of BC is important in several BC subtypes. This study aimed to evaluate the biological and prognostic role of the combined expression of key glutamine transporters, SLC1A5, SLC7A5 and SLC3A2 in BC with emphasis on the intrinsic molecular subtypes. Methods: SLC1A5, SLC7A5 and SLC3A2 were assessed at the protein level, using immunohistochemistry on tissue microarrays constructed from a large well characterised BC cohort (n=2,248). Patients were stratified into accredited clusters based on protein expression and correlated with clinicopathological parameters, molecular subtypes, and patient outcome. Results: Clustering analysis of SLC1A5, SLC7A5 and SLC3A2 identified three clusters Low SLCs (SLC1A5-/SLC7A5-/SLC3A2-), High SLC1A5 (SLC1A5+/SLC7A5-/SLC3A2-) and High SLCs (SLC1A5+/SLC7A5+/SLC3A2+) which had distinct correlations to known prognostic factors and patient outcome (p

Published
2019
Full Text
View/download PDF

49. Expression of epidermal growth factor receptor in breast carcinoma

Author

Lewis, S., Locker, A., Todd, J.H., Bell, J.A., Nicholson, R., Elston, C.W., Blamey, R.W., and Ellis, I.O.

Subjects
Epidermal growth factor -- Receptors, Breast cancer -- Development and progression, Breast cancer -- Prognosis, Health
Abstract

Epidermal growth factor (EGF), a subset of the polypeptide growth factors which help to regulate normal cell growth and differentiation, is essential in the development of mouse mammary glands. In man, EGF has been shown to stimulate normal mammary epithelium and some cancer cell lines. Epidermal growth factor receptors (EGFR) have been identified in normal human breast tissue and in breast cancers. Recent studies have suggested that the presence of EGFR in malignant breast tumors is associated with poor outcomes. In addition, a negative relation has been reported between EGFR and estrogen and progesterone receptor expression in breast cancer. Tumor size, lymph node stage, tumor type and histological grade are predictors of the prognosis of breast cancer. The relation between EGFR and these predictive factors was evaluated by examining 90 patients with primary operable breast cancer. Various surgical procedures were employed to treat the breast tumors, which were measured and stained with monoclonal antibody to EGFR. Estrogen and progesterone receptor content were also determined. Positive EGFR immunoreactivity was identified in 16 patients. An inverse relation was observed between EGFR presence and the expression of estrogen and progesterone receptors. A strong relation between the expression of EGFR and a short disease-free interval was noted. No significant association was found between EGFR and tumor size, lymph node stage or histological grade. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results